Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 901–1,000 of 1,003
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy
Colley, A., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.001 · Cited by 23
Targeted Chemical-Genetic Regulation of Protein Stability In Vivo
Rodriguez, S., & Wolfgang, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.022 · Cited by 23
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment
Butrym, A. K., Rybka, J., Łacina, P., Gębura, K., Frontkiewicz, D., Bogunia‐Kubik, K., & Mazur, G. J. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.007 · Cited by 23
Differential effects of lenalidomide during plasma cell differentiation
Jourdan, M., Cren, M., Schafer, P. H., Robert, N., Duperray, C., Vincent, L., Céballos, P., Cartron, G., Rossi, J., Moreaux, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8581 · Cited by 23
The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis
Gomes, J. D. A., Kowalski, T. W., Fraga, L. R., Macedo, G. S., Sanseverino, M. T. V., Schüler‐Faccini, L., & Vianna, F. S. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47739-8 · Cited by 23
Manda, S., Lee, N. K., Oh, D., & Lee, J. (2020) · Molecules · doi:10.3390/molecules25081948 · Cited by 23
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma—A Unique Entity
Germans, S. K., Kulak, O., Koduru, P. R. K., Oliver, D., Gagan, J., Patel, P. A., Anderson, L. D., Fuda, F. S., Chen, W., & Jaso, J. M. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa109 · Cited by 23
Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs
Peach, M. L., Beedie, S., Chau, C. H., Collins, M. K., Markolovic, S., Luo, W., Tweedie, D., Steinebach, C., Greig, N. H., Gütschow, M., et al. (2020) · Molecules · doi:10.3390/molecules25235683 · Cited by 23
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 23
Blanco, S., Macario, A., & López, J. C. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01691a · Cited by 23
Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jöst, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000252 · Cited by 23
Li, Y., Cai, W., Jin, F., Wang, X., Liu, W., Li, T., Yang, X., Liu, H., Xu, H., & Fang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105656 · Cited by 23
mRNA distribution of the thalidomide binding protein cereblon in adult mouse brain
Aizawa, M., Abe, Y., Ito, T., Handa, H., & Nawa, H. (2011) · Neuroscience Research · doi:10.1016/j.neures.2010.12.019 · Cited by 23
Self-citationZhou, L., & Xu, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1317-7 · Cited by 23
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Vargesson, N., & Fraga, L. R. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0026056 · Cited by 23
Leveraging Structural and Computational Biology for Molecular Glue Discovery
Kang, C., & Xu, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00076 · Cited by 23
Chrisochoidou, Y., Scarpino, A., Morales, S., Martin, S., Bird, S. A., Li, Y., Walker, B. A., Caldwell, J., Bihan, Y. L., & Pawlyn, C. (2025) · Blood · doi:10.1182/blood.2024025861 · Cited by 22
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 22
Discovery of an LSD1 PROTAC degrader
Hosseini, A., Qiu, X., Xiong, Y., Chiang, K. H. N., Catlett, J. L., Kaltheuner, I. H., Deng, Z., Ghosh, S., Shi, Y., & Jin, J. J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425812122 · Cited by 22
MolGlueDB: an online database of molecular glues
Wang, X., Zhuang, Z., Zhang, C., Zhang, B., Zhan, W., Wang, Y., Liu, Z., Yuan, S., Niu, W., He, Q., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf811 · Cited by 22
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 22
IKAROS: from chromatin organization to transcriptional elongation control
Affar, M., Bottardi, S., Quansah, N., Lemarié, M., Ramòn, A. C., Affar, E. B., & Milot, É. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01212-2 · Cited by 22
Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers
Yan, L., Cui, Y., & Feng, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292022 · Cited by 22
Chang, X., Qu, F., Li, C., Zhang, J., Zhang, Y., Xie, Y., Fan, Z., Bian, J., Wang, J., Li, Z., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22024 · Cited by 22
Chen, Y., Xia, Z., Suwal, U., Rappu, P., Heino, J., Wever, O. D., & Geest, B. G. D. (2024) · Chemical Science · doi:10.1039/d4sc03555k · Cited by 22
Ocio, E. M., Mateos, M., & Miguel, J. F. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.691164 · Cited by 22
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade
Zheng, J. J., Sha, Y., Roof, L., Foreman, O., Lazarchick, J. J., Venkata, J. K., Kozlowski, C., Gasparetto, C., Chao, N. J. A., Ebens, A. J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.003 · Cited by 22
Kim, S. Y., Lee, J. Y., Jhin, C., Shin, J. M., Kim, M., Ahn, H. R., Yoo, G., Son, Y., Jung, S. H., & Nho, C. W. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01488 · Cited by 22
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 22
Sweeney, M. A., Iakova, P. A., Maneix, L., Shih, F.-Y., Cho, H. E., Sahin, E., & Catic, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70610-0 · Cited by 22
Emerging Methods in Chemoproteomics with Relevance to Drug Discovery
Nguyen, C., West, G. M., & Geoghegan, K. F. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6539-7_2 · Cited by 22
Function and structural regulation of the carbon monoxide (CO)-responsive membrane protein PGRMC1
Kabe, Y., Handa, H., & Suematsu, M. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-132 · Cited by 22
Self-citationFeng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22
Garber, K. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02164-9 · Cited by 22
Zhou, Q., Wang, W., & Deng, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04838-0 · Cited by 21
Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., van Velzen, J. F., Emmelot, M. E., van Kessel, B., Levin, M., Bos, G. M. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26131 · Cited by 21
Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 21
Anti-Angiogenic Activity of Drugs in Multiple Myeloma
Saltarella, I., Altamura, C., Campanale, C., Laghetti, P., Vacca, A., Frassanito, M. A., & Desaphy, J. (2023) · Cancers · doi:10.3390/cancers15071990 · Cited by 21
Mark, T. M., Coleman, M., & Niesvizky, R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.008 · Cited by 21
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies
Vallet, S., Witzens‐Harig, M., Jaeger, D., & Podar, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656091 · Cited by 21
Zinzani, P. L., Rigacci, L., Cox, M. C., Devizzi, L. F., Fabbri, A., Zaccaria, A., Zaja, F. F., Rocco, A. D., Rossi, G., Storti, S., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.964702 · Cited by 21
Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation
Ando, H., Sato, T., Ito, T., Yamamoto, J., Sakamoto, S., Nitta, N., Asatsuma‐Okumura, T., Shimizu, N., Mizushima, R., Aoki, I., et al. (2019) · iScience · doi:10.1016/j.isci.2019.04.007 · Cited by 21
Self-citationOkazuka, K., Ishida, T., Nashimoto, J., Uto, Y., Sato, K., Miyazaki, K., Ogura, M., Yoshiki, Y., Abe, Y., Tsukada, N., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13349 · Cited by 21
Costa, B. A., Mouhieddine, T. H., & Richter, J. R. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00897-8 · Cited by 21
Inhibition of cereblon by fenofibrate ameliorates alcoholic liver disease by enhancing AMPK
Kim, Y. D., Lee, K. M., Hwang, S., Chang, H. W., Kim, K., Harris, R. A., Choi, H., Choi, W.-S., Lee, S., & Park, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.09.014 · Cited by 21
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0196-6 · Cited by 21
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
Gay, F., Mina, R., Troia, R., & Bringhen, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827169 · Cited by 21
Recent advances in target identification of bioactive natural products
Yoshida, M. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1533804 · Cited by 21
Potential of NK cells in multiple Myeloma therapy
Khan, A., Devarakonda, S. S., Bumma, N., Chaudhry, M., & Benson, D. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1617128 · Cited by 21
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Lindner, S., Steinebach, C., Kehm, H., Mangold, M., Gütschow, M., & Krönke, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59472 · Cited by 16
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen
Mo, Z., Wood, S., Namiranian, S., Mizukoshi, R., Weng, S., Jang, I. S., Fontanillo, C., Baughman, J. M., Silva-Torres, A., Slade, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003431 · Cited by 21
Cereblon expression in multiple myeloma: not ready for prime time
Lodé, L., Amiot, M., Maïga, S., Touzeau, C., Ménard, A., Magrangeas, F., Minvielle, S., Pellat‐Deceunynck, C., Béné, M. C., & Moreau, P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12478 · Cited by 21
Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer
Yang, X., Wang, L., Lin, P., Ning, Y., Lin, Y., Xie, Y., Zhao, C., Mu, L., & Xu, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117710 · Cited by 20
Ishikawa, C., Barreyro, L., Sampson, A. M., Hueneman, K. M., Choi, K., Philbrook, S. Y., Choi, I., Bolanos, L. C., Wunderlich, M., Volk, A. G., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184665 · Cited by 21
Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms
Cheng, J., Bin, X., & Tang, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189169 · Cited by 20
PCMT1 generates the C-terminal cyclic imide degron on CRBN substrates
Zhao, Z., Xu, W., Feng, E. Y., Cao, S., Hermoso-López, A., Peña-Vega, P., Lloyd, H. C., Porter, A. K. D., Guzmán, M., Zheng, N., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02106-9 · Cited by 20
Chen, C. I., Paul, H. K., Wang, T., Le, L. W., Dave, N., Kukreti, V., Wei, E. N., Lau, A., Bergsagel, P. L., & Trudel, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12785 · Cited by 20
Towards Targeted Therapy of Chronic Lymphocytic Leukemia
Niemann, C. U., Jones, J. E., & Wiestner, A. U. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8051-8_12 · Cited by 20
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
Butrym, A. K., Łacina, P., Rybka, J., Chaszczewska-Markowska, M., Mazur, G. J., & Bogunia‐Kubik, K. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0442-6 · Cited by 20
Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner
Zhou, L., Hao, Z., Wang, G., & Xu, G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx433 · Cited by 20
Selvaraj, J., Durai, U., Latha, S., Ayyamperumal, S., Wadhwani, A., & Prabha, T. (2020) · Current Drug Research Reviews · doi:10.2174/2589977512999200821170221 · Cited by 20
Murugesan, A., Lassalle-Claux, G., Hogan, L., Vaillancourt, E., Selka, A., Luiker, K., Kim, M. J., Touaibia, M., & Reiman, T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00350 · Cited by 20
Heim, C., & Hartmann, M. D. (2022) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798322000092 · Cited by 20
Pavić, A., Stojanović, Z. S., Pekmezovic, M. G., Veljovic, D. N., O’Connor, K. E., Malagurski, I., & Nikodinović‐Runić, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040696 · Cited by 20
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma
Katsuya, H. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03572-4 · Cited by 20
Sawamura, N., Wakabayashi, S., Matsumoto, K., Yamada, H., & Asahi, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.068 · Cited by 20
Molecular mechanisms of effectiveness of novel therapies in multiple myeloma
Bianchi, G., & Ghobrial, I. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.706287 · Cited by 20
Kozol, R. A. (2018) · Journal of Developmental Biology · doi:10.3390/jdb6040029 · Cited by 20
Advanced proteomics approaches to unravel protein homeostasis
Grandi, P., & Bantscheff, M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.001 · Cited by 20
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 20
Self-citationGreenberg, A. J., Walters, D. K., Kumar, S. K., Rajkumar, S. V., & Jelinek, D. F. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12192 · Cited by 20
Vertebrate embryos as tools for anti-angiogenic drug screening and function
Beedie, S., Diamond, A. J., Fraga, L. R., Figg, W. D., & Vargesson, N. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.11.013 · Cited by 20
Novel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 20
Pan, Y., Wang, Y., & Gou, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108491 · Cited by 19
Recent advances in the chemistry and biology of plant oxylipin hormones
Nishizato, Y., Okumura, T., Matsumoto, K., & Ueda, M. (2025) · Natural Product Reports · doi:10.1039/d5np00006h · Cited by 19
Recognition of Chiral Carboxylates by Synthetic Receptors
Niedbała, P., Dąbrowa, K., Wasiłek, S., & Jurczak, J. (2021) · Molecules · doi:10.3390/molecules26216417 · Cited by 19
HiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degrader Development
Tsang, T., Huerta, F., Liu, Y., Che, J., Metivier, R. J., Ferrao, S., Donovan, K. A., Jones, L. H., Zerfas, B. L., & Nowak, R. P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00084 · Cited by 19
Molecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 19
Tan, Z. Y., Adade, J. K. A., Gu, X., Hecht, C. J. S., Salcius, M., Tong, B., Liu, S., Hwang, S., Zécri, F. J., Graham, D. B., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.12.002 · Cited by 19
Li, H., Gordon, K. V., Zhang, H., Wang, L., Hu, N., Liz‐Marzán, L. M., & Ni, W. (2025) · ACS Nano · doi:10.1021/acsnano.4c14015 · Cited by 19
Lee, K. M., Yang, S., Park, S., Choi, Y. D., Shin, H. K., Pak, J. H., Park, C., & Kim, I. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.054 · Cited by 19
Emerging biological insights and novel treatment strategies in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., & Morabito, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.713345 · Cited by 19
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 19
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Molfetta, R., Paolini, R., Santoni, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1562-9 · Cited by 19
Won, H.-R., Lee, D. H., Yeon, S.-K., Ryu, H., Kim, G. W., & Kwon, S. H. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4828 · Cited by 19
Hypnotic effect of thalidomide is independent of teratogenic ubiquitin/proteasome pathway
Hirose, Y., Kitazono, T., Sezaki, M., Abe, M., Sakimura, K., Funato, H., Handa, H., Vogt, K. E., & Yanagisawa, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917701117 · Cited by 19
Self-citationHeim, C., Maiwald, S. A., Steinebach, C., Collins, M. K., Strope, J. D., Chau, C. H., Figg, W. D., Gütschow, M., & Hartmann, M. D. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.117 · Cited by 19
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 19
Self-citationMitochondrial cereblon functions as a Lon-type protease
Kataoka, K., Nakamura, C., Asahi, T., & Sawamura, N. (2016) · Scientific Reports · doi:10.1038/srep29986 · Cited by 19
Yamazaki, H., Suemizu, H., Kazuki, Y., Oofusa, K., Kuribayashi, S., Shimizu, M., Ninomiya, S., Horie, T., Shibata, N., & Guengerich, F. P. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00210 · Cited by 19
Millrine, D., Tei, M., Gemechu, Y., & Kishimoto, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611751113 · Cited by 19
Misiewicz-Krzemińska, I., Corchete, L. A., Rojas, E. A., Martínez‐López, J., García‐Sánz, R., Oriol, A., Bladé, J., Lahuerta, J. J., Miguel, J. F. S., Mateos, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181628 · Cited by 19
Tao, J., Yang, J., & Xu, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.058 · Cited by 19
Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide
Yamamoto, K., Kitawaki, T., Sugimoto, N., Fujita, H., Kawase, Y., Takaori‐Kondo, A., & Kadowaki, N. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.012 · Cited by 19
CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation
Kowalski, T. W., Gomes, J. D. A., Caldas-Garcia, G. B., Fraga, L. R., Paixão‐Côrtes, V. R., Recamonde‐Mendoza, M., Sanseverino, M. T. V., Schüler‐Faccini, L., & Vianna, F. S. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-57512-x · Cited by 19
Identification of an allosteric site on the E3 ligase adapter cereblon
Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., et al. (2026) · Nature · doi:10.1038/s41586-025-09994-w · Cited by 14
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…specificity for the cRl4 complex (Angers et al. 2006). cRBN was found to bind thalidomide, altering the substrate specificity of the ligase (ito et al. 2010). whilst it was initially hypothesized that thalidomide inhibited the ubiquitylating activity of cRl4 cRBN , the true nature of this…”
Influential
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.